肺水肿治疗市场按药物类别、类型、给药途径、通路和地区划分

肺水肿治疗市场预计在 2026 年达到 37.52 亿美元，预计到 2033 年将达到 46.9 亿美元，2026 年至 2033 年的复合年增长率为 3.2%。

由于越来越多的人患有心臟、呼吸系统和生活方式相关的健康问题，全球治疗肺水肿的药物市场正在迅速成长。肺水肿是指肺部积水的疾病，通常由心臟衰竭、感染疾病或创伤引起，因此及时就医至关重要。

市面上有多种治疗方法，包括利尿剂、血管扩张剂、ACE抑制剂、鸦片类药物和正性肌力药物等药物，以及氧气疗法、人工呼吸器和肺部復健等非药物治疗方法。人们对早期诊断的意识提升，加上医疗基础设施的改善，正在推动对有效治疗方法的需求。

儘管仍有许多挑战，例如治疗费用高昂以及低收入地区医疗资源有限，但新药研发、个人化医疗和远端医疗管理解决方案等领域蕴藏着巨大的机会。在新药研发和全球医疗保健成本不断上涨的推动下，肺水肿治疗市场预计将继续快速成长，从而改善患者预后并塑造呼吸系统疾病治疗的未来。

市场动态

由于心血管和呼吸系统疾病的盛行率不断上升以及人口老化，肺水肿治疗市场持续稳定成长。人们对早期诊断和早期疗育重要性的认识不断提高，推动了药物和非药物疗法需求的成长。利尿剂、血管扩张剂、血管张力素转换酶抑制剂、鸦片类药物和强心药等药物疗法仍是治疗的基础，而氧气疗法、人工呼吸器和肺部復健等支持性疗法也日益普及。

药物研发的进步、医疗基础设施的改善以及远端医疗在远端患者监护的应用，都推动了市场成长。此外，对个人化医疗和标靶治疗日益增长的关注，也为创新创造了机会。

然而，挑战依然存在，包括高昂的费用、低收入社区难以获得治疗以及侵入性手术带来的风险。监管障碍和大规模临床试验的需求也减缓了新治疗方法的推广应用。

儘管存在这些障碍，但在扩展数位健康解决方案、开发更安全的药物类别以及利用人工智慧驱动的诊断技术进行早期检测等领域仍然存在机会。

本次调查的主要特点

• 本报告对肺水肿治疗市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）内的市场规模（十亿美元）和復合年增长率（%）。
• 它还重点介绍了各个细分市场的潜在商机，并解释了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 该报告根据以下参数对肺水肿治疗市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告的研究结果将使负责人和经营团队能够就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
• 这份肺水肿治疗药物市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 相关人员将能够透过用于分析肺水肿治疗药物市场的各种策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场范围

• 报告概述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章 市场动态、监理及趋势分析

• 市场动态
• 司机
• 抑制因素
• 市场
• 法规环境
• 产业趋势
• 併购
• 新系统实施和核准

4. 2026-2033年全球肺水肿治疗药物市场（依药物类别划分）

• 利尿剂
• 阿片类镇痛药
• 血管扩张剂
• 心臟兴奋剂
• 其他的

5. 2026-2033年全球肺水肿治疗市场（依类型划分）

• 心源性肺水肿
• 非心源性肺水肿

6. 2026-2033年全球肺水肿治疗药物市场（依给药途径划分）

• 口服
• 静脉注射

7. 2026-2033年全球肺水肿治疗药物市场（依通路划分）

• 医院药房
• 零售药房
• 网路药房

8. 2026-2033年全球肺水肿治疗市场（按地区划分）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 中东和非洲
  • 南非
  • 海湾合作委员会国家
  • 其他中东和非洲地区

第九章 竞争情势

• 公司简介
  • Novartis International AG
  • Cytokinetics Inc.
  • Amgen Inc.
  • AstraZeneca plc.
  • Celularity Inc
  • United Therapeutics Corporation

第十章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十一章调查方法

• 参考
• 调查方法

Pulmonary Edema Therapeutics Market is estimated to be valued at USD 3.752 Bn in 2026 and is expected to reach USD 4.690 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.2% from 2026 to 2033.

The global market for pulmonary edema treatments is growing rapidly. This is due to increasingly individuals are getting heart disease, respiratory problems, and health problems related to their lifestyle. Pulmonary edema, which is when fluid builds up in the lungs, is often caused by heart failure, infections, or trauma. This makes it extremely essential to get help right away.

There are many different types of treatments available on the market. These include drugs like diuretics, vasodilators, ACE inhibitors, opioids, and inotropes, as well as non-drug treatments like oxygen therapy, mechanical ventilation, and pulmonary rehabilitation. Rising awareness about early diagnosis, along with improvements in healthcare infrastructure, is driving up the need for effective treatments.

Even though, there are problems like high treatment costs and limited access in low-income areas, there are chances to create new drug classes, personalized medicine, and telemedicine-based management solutions. The pulmonary edema therapeutics market is expected to keep growing quickly driven by new drug development and more funds being spent on healthcare around the world. This will lead to better patient outcomes and shape the future of respiratory care.

Market Dynamics

The pulmonary edema therapeutics market is experiencing steady expansion, propelled by the rising prevalence of cardiovascular diseases, respiratory disorders, and aging populations. Increased awareness of early diagnosis and intervention has led to rise in demand for both pharmacological and non-pharmacological treatments. Pharmacological therapies such as diuretics, vasodilators, ACE inhibitors, opioids, and inotropes remain the cornerstone of treatment, while supportive care options like oxygen therapy, mechanical ventilation, and pulmonary rehabilitation are becoming popular.

Advancements in drug development, improved healthcare infrastructure, and the integration of telemedicine for remote patient monitoring are all contributing to the growth of the market. Additionally, the growing focus on personalized medicine and targeted therapies is opening opportunity for innovation.

However, the market faces challenges such as high treatment costs, limited access in low-income regions, and risks associated with invasive procedures. Regulatory hurdles and the need for extensive clinical trials also slow down the introduction of novel therapies.

Despite these barriers, opportunities lie in expanding digital health solutions, developing safer drug classes, and leveraging AI-driven diagnostics for early detection.

Key Features of the Study

• This report provides in-depth analysis of the pulmonary edema therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the pulmonary edema therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis International AG, Cytokinetics Inc., Amgen Inc., AstraZeneca plc., Celularity Inc., and United Therapeutics Corporation.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The pulmonary edema therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the pulmonary edema therapeutics market.

Market Segmentation

• By Drug Class
  • Diuretics
  • Opioid Analgesics
  • Vasodilators
  • Inotropes
  • Others
• By Type
  • Cardiogenic Pulmonary Edema
  • Non-cardiogenic Pulmonary Edema
• By Route of Administration
  • Oral
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • South Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Competitive landscape
  • Novartis International AG
  • Cytokinetics Inc.
  • Amgen Inc.
  • AstraZeneca plc.
  • Celularity Inc.
  • United Therapeutics Corporation

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Market
• Regulatory Scenario
• Industry Trend
• Merger and Acquisitions
• New System Launches/Approvals

4. Global Pulmonary Edema Therapeutics Market, By Drug Class, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Diuretics
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Opioid Analgesics
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Vasodilators
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Inotropes
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

5. Global Pulmonary Edema Therapeutics Market, By Type, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Cardiogenic Pulmonary Edema
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Non-cardiogenic Pulmonary Edema
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

6. Global Pulmonary Edema Therapeutics Market, By Route of Administration, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

7. Global Pulmonary Edema Therapeutics Market, By Distribution Channel, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

8. Global Pulmonary Edema Therapeutics Market , By Region, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
• North America
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • U.S.
    • Canada
• Europe
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • U.K.
    • Germany
    • France
    • Russia
    • Rest of Europe
• Asia Pacific
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • South Africa
    • GCC Countries
    • Rest of the Middle East and Africa

9. Competitive Landscape

• Company Profiles
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • Cytokinetics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • AstraZeneca plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • Celularity Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • United Therapeutics Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Research Methodology

• References
• Research Methodology
• About us and Sales Contact